Dengue Virus-Like Particles

Dengue fever is ranked by the World Health Organization (WHO) as the most critical mosquito-borne viral disease, globally. More than 40 percent of the world’s population, in more than 100 countries are at risk of dengue infection. There are no vaccines available to prevent infection with dengue virus (WHO, 2022).

Virus-Like Particles (VLPs) are an emerging vaccine technology, and very effective in next-generation IVD assay development. The Native Antigen Company offers an exclusive range of Virus Like Particles for all Dengue Virus serogroups, as well as a multipack containing 100ug each of VLPs from serotypes 1-4. Years of success in producing the VLPs allowed us to optimise the manufacturing methods; therefore, we can offer a high-grade product for your research needs.

About the Dengue Virus Like Particles

VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and while they are highly immunogenic, they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others (Metz et al).

See our full range of Virus like particles. Click here.

References

Metz et al (2018). Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol J. 2018 Apr 2;15(1):60 PMID: 29609659

Serogroups of the Dengue Virus	Product Description	Regular Price
Dengue Virus Serotype 1 VLP – The Native Antigen Company	Recombinant Dengue Virus serotype 1 virus-like particles consisting of Envelope, pre-Membrane and Membrane proteins, produced in mammalian HEK293 cells	£803.25 – £2,765.25 excl. VAT	Order now
Dengue Virus Serotype 2 VLP – The Native Antigen Company	Recombinant Dengue Virus serotype 2 virus-like particles consisting of Envelope, pre-Membrane and Membrane protein produced in mammalian HEK293 cells	£664.88 – £2,891.25 excl. VAT	Order now
Dengue Virus Serotype 3 VLP – The Native Antigen Company	Recombinant Dengue Virus serotype 3 virus-like particles consisting of Envelope, pre-Membrane and Membrane protein produced in mammalian HEK293 cells.	£803.25 – £3,432.38 excl. VAT	Order now
Dengue Virus Serotype 4 VLP – The Native Antigen Company	Recombinant Dengue Virus serotype 4 virus-like particles consisting of Envelope, pre-Membrane and Membrane protein produced in mammalian HEK293 cells.	£803.25 – £2,810.25 excl. VAT	Order now
Dengue virus-like particles serotypes 1-4 – The Native Antigen Company	Multi-pack of all Dengue Virus VLPs, containing 100ug each of VLPs from serotypes 1-4.	£2,488.50 excl. VAT	Order now

We also offer a range of Dengue proteins and antibodies to support ongoing research into the epidemiology, vaccines, diagnostics, and therapeutics. Click here for further information.

Get in touch

First name

Last name

Email address

What you're looking for

Would you like to be kept informed of the latest news and innovations from the infectious disease community? Please let us know if you would like us to contact you or not by selecting one of the options below. Would you like to be kept informed of the latest news and innovations from the infectious disease community? Please let us know if you would like us to contact you or not by selecting one of the options below. Yes please, I would like to stay up to date with the latest infectious disease research and innovations. No thank you, I do not want to hear about the latest infectious disease research and innovations.

3 + 2 =

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

by Bobby Mitchell | 2nd November 2022 | COVID-19 | 0 Comments

New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases Oxford, UK, 02 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables...

The Role of Serology in Tracking COVID-19 Mutations

by James Shore | 27th August 2021 | COVID-19, Disease trends, Immunoassays, Research, Vaccines | 0 Comments

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Preparing for Disease Y: A Better Serological Toolbox

by James Shore | 26th July 2021 | COVID-19, Disease trends, Immunoassays, Neglected Tropical Diseases, Research, Vaccines | 0 Comments

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

by James Shore | 3rd June 2021 | Coronaviruses, COVID-19, Disease trends | 0 Comments

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...

Making Sense of the SARS-CoV-2 Spike Mutations

by James Shore | 25th March 2021 | Coronaviruses, COVID-19, Disease insight, Disease trends, Immunoassays, New products, Research, Vaccines | 0 Comments

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...

D614G: Putting the Mutation in Perspective

by James Shore | 10th November 2020 | Coronaviruses, COVID-19, Disease insight, Disease trends, New products, Research | 0 Comments

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...

The Endemic Coronaviruses and What They Might Tell us About COVID-19

by James Shore | 29th July 2020 | Coronaviruses, COVID-19, Disease insight, Immunoassays, New products | 0 Comments

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...

Q&A: An Insight Into COVID-19 Serology

by James Shore | 8th July 2020 | Coronaviruses, COVID-19, Immunoassays, Research | 0 Comments

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

by James Shore | 20th May 2020 | Cancer, COVID-19, Disease insight, Research, Toxins | 0 Comments

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

by James Shore | 4th May 2020 | Coronaviruses, COVID-19, Disease insight, Immunoassays, Vaccines | 0 Comments

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

by James Shore | 15th April 2020 | Coronaviruses, COVID-19, Immunoassays, Research, Vaccines | 0 Comments

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

by James Shore | 14th April 2020 | Coronaviruses, COVID-19, Vaccines | 0 Comments

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Why We Need Antigen and Antibody Tests for COVID-19

by James Shore | 24th March 2020 | Coronaviruses, COVID-19, Disease insight, Immunoassays, New products | 0 Comments

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Novel Coronavirus Antigens Now Available

by James Shore | 11th February 2020 | Coronaviruses, Disease insight, New products | 0 Comments

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

Coronaviruses: The Next Disease X?

by James Shore | 5th November 2019 | Coronaviruses, Disease insight, New products | 0 Comments

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...